secwatch / observer
8-K filed November 27, 2024, 6:59 PM ET CIK 0000827871
other material confidence high sentiment negative materiality 0.75

EAGLE PHARMACEUTICALS, INC.: auditor change — Eagle Pharmaceuticals dismisses EY, appoints BDO as auditor amid restatement

EAGLE PHARMACEUTICALS, INC.

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

EAGLE PHARMACEUTICALS, INC. reported that prior financial statements should not be relied upon.

Action
non reliance
Auditor
Ernst & Young LLP
Exact text from the filing
on September 27, 2024, the Audit Committee, based on the recommendation of, and after consultation with, the Company’s management, concluded that the Company’s audited financial statements for the fiscal year ended December 31, 2022, and unaudited financial statements for the quarters ended June 30, 2022, September 30, 2022, and March 31, 2023, as previously filed with the SEC, should no longer be relied upon and should be restated.
View on SEC.gov
Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

EAGLE PHARMACEUTICALS, INC. dismissed Ernst & Young LLP as its auditor.

Action
dismissal
Auditor
Ernst & Young LLP
Exact text from the filing
On November 21, 2024, Eagle Pharmaceuticals, Inc., a Delaware corporation (the “Company”), dismissed Ernst & Young LLP (“EY”), the Company’s previous independent registered public accounting firm.
View on SEC.gov
Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

EAGLE PHARMACEUTICALS, INC. engaged BDO USA, P.C. as its auditor.

Action
engagement
Auditor
BDO USA, P.C.
Exact text from the filing
On November 26, 2024, the Company engaged BDO USA, P.C. (“BDO”) as the Company’s independent registered public accounting firm
View on SEC.gov

Browse all auditor changes →

Source: SEC EDGAR
accession 0001104659-24-123472
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.